Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Por Wells, Samuel A., Robinson, Bruce G., Gagel, Robert F., Dralle, Henning, Fagin, James A., Santoro, Massimo, Baudin, Eric, Elisei, Rossella, Jarzab, Barbara, Vasselli, James R., Read, Jessica, Langmuir, Peter, Ryan, Anderson J., Schlumberger, Martin J.
Publicado em 2012

Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial

Por Brose, Marcia S, Nutting, Christopher M, Jarzab, Barbara, Elisei, Rossella, Siena, Salvatore, Bastholt, Lars, de la Fouchardiere, Christelle, Pacini, Furio, Paschke, Ralf, KeeShong, Young, Sherman, Steven I, Smit, Johannes WA, Chung, John, Kappeler, Christian, Pena, Carol, Molnár, István, Schlumberger, Martin J
Publicado no Lancet (2014)

Cabozantinib in Progressive Medullary Thyroid Cancer

Por Elisei, Rossella, Schlumberger, Martin J., Müller, Stefan P., Schöffski, Patrick, Brose, Marcia S., Shah, Manisha H., Licitra, Lisa, Jarzab, Barbara, Medvedev, Viktor, Kreissl, Michael C., Niederle, Bruno, Cohen, Ezra E.W., Wirth, Lori J., Ali, Haythem, Hessel, Colin, Yaron, Yifah, Ball, Douglas, Nelkin, Barry, Sherman, Steven I.
Publicado em 2013